Sleep Apnea Identification & Treatment in Dentistry

睡眠呼吸暂停识别

基本信息

批准号：
7218893
负责人：
Daniel J Levendowski
金额：
$ 56.63万
依托单位：
ADVANCED BRAIN MONITORING, INC.
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-03-01 至 2009-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7218893
关键词：
Affect Age American Apnea Awareness Body mass index Brain Communities Continuous Positive Airway Pressure Data Databases Dental Dentistry Dentists Devices Diagnosis Disease Early identification End Point Enrollment Equilibrium Evaluation Failure Family member Goals Health Personnel Home environment Individual Investigation Laboratories Literature Mandible Measures Medical Medicine Memory Methods Modeling Monitor Morbidity - disease rate Neck Neurocognitive Obstructive Sleep Apnea Oral Outcome Outcome Measure Participant Patients Phase Phase I Clinical Trials Physicians Play Primary Care Physician Recruitment Activity Reporting Risk Role Severities Severity of illness Site Sleep Sleep Apnea Syndromes Sleep Disorders Snoring Specialist Symptoms System Testing Titrations Treatment Efficacy Treatment outcome Visit Work alertness base cost design improved indexing mortality novel outreach programs prospective respiratory success

项目摘要

DESCRIPTION (provided by applicant): Obstructive Sleep Apnea (OSA), a highly prevalent, under-diagnosed disorder affecting over 18 million Americans, is responsible for more mortality and morbidity than any other sleep disorder. Dentists are increasingly involved with the treatment of OSA with oral appliances, an accepted treatment of OSA for patients with mild to moderate disease severity and for those patients who cannot or will not be treated with Continuous Positive Airway Pressure (CPAP). Advanced Brain Monitoring (ABM) developed and validated the Apnea Risk Evaluation System (ARES), a convenient, cost-effective alternative to laboratory sleep studies to facilitate rapid, cost-effective diagnosis of OSA at home. ARES proved effective during the Phase I study in confirming diagnosis of OSA in a dental setting and in evaluating treatment outcome and assessing titration levels in patients fitted with mandibular-advancing devices (MAD). The primary goals for Phase II will be to: 1) acquire a large database of ARES treatment outcome studies from 100 patients treated with MAD, 2) document treatment efficacy using the Alertness and Memory Profiling (AMP) system, a highly sensitive and objective method for quantifying outcome, 3) develop a system for monitoring and improving MAD titration, and 4) develop a model for predicting treatment success with oral appliances. The result of this effort will be to provide a basis for expanded use of MAD therapy by selecting patients most likely to benefit from this treatment and providing measures to maximize the benefit to those selected. Dentists and dental sleep specialists represent an important access point for identifying patients with undiagnosed OSA. Although many individuals do not routinely visit their primary care physicians, the majority receive routine biannual dental examinations. Dental professionals can therefore play an important role in the identification of patients at-risk for OSA. The ARES provides a cost-effective method for dentists and dental sleep specialists to test patients for OSA and evaluate treatment efficacy. The Phase II project is designed to build upon the success achieved during Phase I in working with the dental community to provide a comprehensive program that be implemented to facilitate early identification and efficacious treatment for patients with loud snoring and OSA.

描述（由申请人提供）：阻塞性睡眠呼吸暂停 (OSA) 是一种非常普遍、诊断不足的疾病，影响着超过 1800 万美国人，其死亡率和发病率高于任何其他睡眠障碍。牙医越来越多地参与使用口腔矫治器治疗 OSA，这是一种针对轻度至中度疾病严重程度的患者以及不能或不会接受持续气道正压通气 (CPAP) 治疗的患者的公认的 OSA 治疗方法。高级脑监测 (ABM) 开发并验证了呼吸暂停风险评估系统 (ARES)，这是实验室睡眠研究的一种方便且经济高效的替代方案，可促进在家中快速、经济高效地诊断 OSA。在 I 期研究中，ARES 在确认牙科环境中 OSA 的诊断、评估治疗结果以及评估装有下颌前移装置 (MAD) 的患者的滴定水平方面被证明是有效的。 II 期的主要目标是：1) 获取 100 名接受 MAD 治疗的患者的 ARES 治疗结果研究的大型数据库，2) 使用警觉性和记忆分析 (AMP) 系统记录治疗效果，这是一种高度敏感和客观的方法为了量化结果，3) 开发一个用于监测和改进 MAD 滴定的系统，4) 开发一个用于预测口腔矫治器治疗成功的模型。这项努力的结果将是通过选择最有可能从这种治疗中受益的患者并提供措施以最大限度地提高所选患者的获益，为扩大 MAD 疗法的使用奠定基础。牙医和牙科睡眠专家是识别未确诊 OSA 患者的重要途径。尽管许多人不会定期去看初级保健医生，但大多数人每年两次接受常规牙科检查。因此，牙科专业人员在识别有 OSA 风险的患者方面可以发挥重要作用。 ARES 为牙医和牙科睡眠专家提供了一种经济有效的方法来测试患者的 OSA 并评估治疗效果。第二阶段项目旨在以第一阶段与牙科界合作所取得的成功为基础，提供一个全面的计划，以促进大声打鼾和 OSA 患者的早期识别和有效治疗。